Skip to main content

Advertisement

Table 4 Adjusted odds ratios for the autoimmune rheumatic disease group overall and disease subgroups a

From: Increased 30-day and 1-year mortality rates and lower coronary revascularisation rates following acute myocardial infarction in patients with autoimmune rheumatic disease

Condition Count 30-day mortality (adjusted odds ratio b ) 12-month mortality (adjusted odds ratio b )
All causes Cardiovascular All causes Cardiovascular
Autoimmune rheumatic diseases 1,409 1.44 (1.26 to 1.65) 1.44 (1.25 to 1.66) 1.82 (1.61 to 2.05) 1.71 (1.51 to 1.94)
Rheumatoid arthritis 666 1.50 (1.24 to 1.81) 1.51 (1.24 to 1.84) 2.00 (1.69 to 2.35) 1.85 (1.57 to 2.19)
Systemic lupus erythematosus 93 2.81 (1.71 to 4.62) 2.77 (1.65 to 4.64) 2.57 (1.60 to 4.13) 2.14 (1.30 to 3.51)
Psoriatic arthropathies 25 2.61 (1.14 to 5.97) 3.19 (1.40 to 7.27) 2.33 (1.09 to 4.97) 2.59 (1.19 to 5.63)
Ankylosing spondylitis 38 2.14 (1.13 to 4.08) 2.01 (1.02 to 3.95) 2.11 (1.16 to 3.82) 1.98 (1.08 to 3.66)
Spondyloarthritisc 63 2.19 (1.30 to 3.67) 2.26 (1.32 to 3.86) 2.11 (1.31 to 3.39) 2.10 (1.29 to 3.42)
Systemic sclerosis 61 1.78 (0.95 to 3.33) 1.53 (0.78 to 3.03) 2.58 (1.48 to 4.48) 1.85 (1.03 to 3.34)
Systemic necrotising vasculitides 174 1.37 (0.95 to 1.98) 1.24 (0.84 to 1.84) 1.87 (1.35 to 2.60) 1.73 (1.25 to 2.41)
Sjögren’s syndrome 17 1.27 (0.42 to 3.86) 1.03 (0.30 to 3.57) 0.90 (0.32 to 2.53) 0.57 (0.16 to 1.97)
Polymyalgia rheumatica 239 0.96 (0.70 to 1.32) 1.01 (0.73 to 1.40) 1.25 (0.95 to 1.63) 1.38 (1.05 to 1.81)
Mixed connective tissue disease 19 0.78 (0.22 to 2.76) 0.95 (0.27 to 3.36) 2.96 (1.16 to 7.56) 2.06 (0.79 to 5.37)
Dermatomyositis/polymyositis 25 0.25 (0.03 to 1.95) 0.32 (0.04 to 2.42) 2.40 (0.93 to 6.19) 2.45 (0.95 to 6.31)
  1. aStatistically significant results in bold. bAdjusted for age, sex, Accessibility/Remoteness Index of Australia, Socio-Economic Indexes for Areas and comorbidities. cSpondyloarthritis group includes ankylosing spondylitis, psoriatic arthritis, enteropathic arthritis and undifferentiated spondyloarthritis.